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Abstract. 
 
The repair of articular cartilage is challenging due to the sparse native cell population 
combined with the avascular and aneural nature of the tissue. In recent years cartilage 
tissue engineering has shown great promise. As with all tissue engineering strategies, the 
possible therapeutic outcome is intimately linked with the used combination of cells, 
growth factors and biomaterials. However, the optimal combination has remained a 
controversial topic and no consensus has been reached. In consequence, much effort has 
been dedicated to further design, investigate and optimize cartilage repair strategies. 
Specifically, various research groups have performed intensive investigations attempting 
to identify the single most optimal cell source for articular cartilage repair strategies. 
However, recent findings indicate that not the heavily investigated mono cell source, but 
the less studied combinations of cell sources in co-culture might be more attractive for 
cartilage repair strategies. 
This review will give a comprehensive overview on the cell sources that have 
been investigated for articular cartilage repair strategies. In particular, the advantages and 
disadvantages of investigated cell sources are comprehensively discussed with emphasis 
on the potential of co-cultures in which benefits are combined while the disadvantages of 
single cell sources for cartilage repair are mitigated. 
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Introduction 
Mature articular cartilage is composed of an abundant extracellular matrix that is 
sparsely populated by chondrocytes. Articular cartilage is avascular and aneural and the 
native chondrocytes are largely in cell cycle arrest. As a consequence, it is challenging 
for this tissue to suitably respond to traumatic injury. Cartilage damage inevitably results 
in altered biomechanics of the joint and joint instability, which shift joint homeostasis 
towards catabolism (1, 2). If left untreated, this may ultimately lead to joint failure. As a 
result, the recalcitrant capacity of articular cartilage to self-heal acquired injuries drives 
research focused on (novel) cartilage reparative and regenerative treatments.  
Current treatments of traumatic cartilage defects include osteochondral grafting, 
bone marrow stimulation techniques and more recently cell based therapies (3-6). 
Osteochondral autografting is particularly suitable for smaller lesions, but is associated 
with donor-site morbidity (7). Osteochondral allografting can be considered for larger 
defects, but is associated with graft failure and immune reactions (8, 9). Bone marrow 
stimulation techniques such as micro-fracturing and micro-drilling are used for defects 
smaller than 2-4 cm
2
 with little or no bone loss and are associated with the formation of 
fibrocartilage (10). The most common form of cell-based therapies is autologous 
chondrocyte implantation (ACI). This treatment is based on the implantation of expanded 
autologous chondrocytes, which were isolated from a biopsy that was obtained from a 
non-load bearing site of the same donor. Since ACI is dependent on the violation of intact 
cartilage as well as ex-vivo chondrocyte expansion, it is associated with donor-site 
morbidity and loss of chondrogenicity of cultured chondrocytes known as 
dedifferentiation (4). 
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Consequently, a myriad of alternative cell sources other than culture expanded 
articular chondrocytes have been investigated to circumvent these side-effects and 
thereby to improve the therapeutic outcome of cartilage repair strategies. In addition to 
several types of chondrocytes derived from a number of hyaline cartilage subtypes, the 
use of multi-potent cells with chondrogenic potential derived from various tissue sources 
has been proposed. In addition to conventional mono-culture the approach of co-cultures 
has gained significant attention. Interestingly, co-cultures have been shown to be able to 
outperform their respective single cultures. Unfortunately, in depth understanding and 
clinical translation of this phenomenon has remained wanted.   
This review will discuss the different cell sources dominating the field of cartilage 
tissue engineering and highlights recent advances of co-culture approaches. 
 
Autologous articular chondrocytes: cell number versus dedifferentiation 
Conventional cell-based cartilage repair therapies characteristically use 
autologous articular chondrocytes. These cells are harvested from biopsies of 
macroscopically intact cartilage derived from a non-weight bearing part of the joint (11). 
Removal of a biopsy from healthy articular cartilage can potentially lead to secondary 
osteoarthritis. However, more thorough studies with a longer follow-up are required to 
understand the full extent of the consequences of harvesting biopsies (12). To minimize 
the chance of developing secondary osteoarthritis the biopsy size is limited. In 
consequence, the biopsy yields insufficient amounts of chondrocytes to allow for direct 
filling of the defect. Therefore, chondrocytes are expanded in vitro before reimplantation. 
Unfortunately, expansion is associated with progressive loss of the chondrogenic 
phenotype and results in dedifferentiated fibroblast-like chondrocytes (13). We recently 
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demonstrated that articular chondrocyte dedifferentiation is a continuous, progressive and 
multi-signaling-pathway-based process. Moreover, the potential to redifferentiate is also 
gradually lost and might be in part caused by epigenetic mechanisms such as DNA 
methylation. The loss of the chondrocyte phenotype during monolayer expansion is 
suggested to be dependent on the matrix elasticity of the culture environment (14). As 
this process can impede the therapeutic outcome, the prevention of dedifferentiation 
and/or the induction of redifferentiation have been intensively investigated. Investigated 
strategies include exposure to optimized environmental properties like reduced oxygen 
levels (15) and physiological tonicity of the culture medium (16), dynamic non-adherent 
culturing as aggregates (17), decreased seeding density (18), three dimensional expansion 
of cells using e.g. microcarriers (19), varying the elasticity of the growth surface to 
simulate cartilage stiffness (14) or pore-size of carrier material (20), culture on 
predeposited extracellular matrices of e.g. synovium-derived stem cells (21), the use of 
medium preconditioned by primary chondrocytes or MSCs (22-24) or supplementation of 
the expansion medium with exogenous recombinant growth factors, like FGF-2 (25). In 
general, these strategies led to improved expression of chondrogenic markers and a 
(partial) reduction of dedifferentiation markers. However, as large, comprehensive and 
well controlled comparative studies are largely lacking, consensus on an optimal strategy 
remains wanted. 
Dedifferentiation can also be limited or even prevented by reducing or omitting 
the expansion phase. This idea is based on implanting fewer chondrocytes that are less 
expanded and have therefore a superior chondrogenic performance (26-28). Although this 
approach demonstrated to be able to regenerate cartilage, it results in mechanically 
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weaker cartilage when compared to implantation of higher densities of chondrocytes 
expanded over prolonged culture times in the same defect size. By reducing or omitting 
the amount of dedicated cell culture time, it might be possible to improve the costs-
effectiveness of chondrocyte-based cell therapy and reduce the time between taking the 
biopsy and implanting expanded cells in a second surgical procedure. 
 
Non-autologous articular chondrocytes: morbidity versus immune response 
Allogenic, or even xenogenic, articular chondrocytes can be considered as an 
alternative cell source of which the isolation does not inflict additional damage to the 
joint. Advantageously,  a larger number of chondrocytes can be obtained by taking larger 
biopsies and/or pooling different, potentially younger, donors. This might limit or 
obsolete the expansion phase, leading to a better preservation of the chondrocyte 
phenotype, and could potentially reduce inter-patient variation of the therapeutic outcome. 
Naturally,  serious consideration should be given to drawbacks such as disease 
transmission and immune rejection (29). Indeed, chondrocytes constitutively express 
histocompatibility complex class I at their cell surface and demonstrate cytokine 
inducible expression of histocompatibility complex class II (30). Moreover, it has been 
shown that chondrocytes can interact with immune cells (31). Several reports have 
described serious immune responses after allogenic chondrocyte implantation in full 
thickness defects where the access to the bone marrow increases the risk for 
immunological reactions (32-34). Consequently, the clinical feasibility of allogenic 
chondrocytes implantation is questionable. In contrast, osteochondral allograft 
demonstrated only minor immunogenic signs in human clinical trials (35, 36). On the one 
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hand the immunological responses might be caused by the osseous part of the graft with 
residing bone marrow (9), whereas on the other hand the protective environment of the 
native cartilage will limit immunological reactions. The avascular and highly dense 
nature of the extra cellular matrix might be able to limit or prevent the invasion of 
immune cells from the joint to interact with chondrocytes. Indeed, isolated chondrocytes 
appear to be protected from an immune response when encapsulated in biocompatible 
biomaterials or when allowed to form a new extracellular matrix in vitro (37, 38). Due to 
their more wide availability and the limited immunogenic risk when embedded in an 
extracellular matrix, non-autologous articular chondrocytes can be still considered as a 
potentially interesting cell source for matrix assisted chondrocyte transplantations. 
 
Non-articular chondrocytes: morbidity versus phenotype 
Next to articular chondrocytes, several alternative chondrocyte sources have been 
investigated to design cartilage repair strategies that do not impose additional damage to 
the articular cartilage. In adults, other sources of (non-articular) hyaline cartilage are 
located in the nose, ribs, larynx, trachea and bronchi. In particular, costal and nasoseptal 
chondrocytes have been extensively investigated (29, 39-41). Both costal and nasoseptal 
cartilage biopsies, respectively harvested from the ribcage or from the septum of the nose, 
grant a higher cell yield of chondrocytes. The proliferation rate of these chondrocytes is 
increased compared to articular chondrocytes (42). Although they both undergo 
dedifferentiation during expansion they appear more susceptible to redifferentiation (43, 
44). Moreover, transplantation of costal chondrocytes in full thickness defects results in 
the production of neocartilage (45). Unfortunately, both costal and nasoseptal 
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chondrocytes are known for their ability to ossify when reimplanted (40, 46, 47). The 
different anatomical location and function of costal and nasoseptal cartilage might 
underlie their limited potential to form articular cartilage. In particular, the mechanical 
loading in the articular cartilage is frequent and highly compressive, whereas costal and 
nasoseptal cartilage experiences at best low tensile loads. 
Auricular chondrocytes derived from elastocartilage of the ear are as well 
considered as a possibly interesting cell source for cartilage repair strategies. Native and 
freshly isolated auricular chondrocytes typically express elastin. Although, upon in vitro 
culture the expression of elastin is gradually lost (41, 48), it has been reported that the 
elastin expression can be regained when implanted in vivo (49). Whether the expression 
of elastin will negatively influence the mechanical properties of neocartilage in an 
articular cartilage defect remains to be clarified. Like nasoseptal and costal cartilage, 
isolated auricular cartilage provides a higher cell yield per gram of biopsied tissue and 
have a higher proliferation rate compared to articular cartilage. Auricular chondrocytes 
are prone to dedifferentiation and are susceptible to redifferentiation (42, 50). Mild forms 
of ossification have been observed after reimplantation (40). Even though auricular 
cartilage has a rather non-loaded, supportive function for the external ear, it has been 
found that auricular chondrocytes express lubricin, a mucinous glycoprotein essential for 
lubrication of the joint (41). Therefore, auricular chondrocytes are a cell source of 
considerable interest, in particular for repair or reconstruction of the superficial zone of 
articular cartilage.  
Meniscal chondrocytes derived from the meniscal fibrocartilage also express 
lubricin and have been investigated in cartilage repair strategies (41, 51). However, 
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meniscal chondrocytes scarcely express collagen II, and have limited potential to secrete 
glycosaminoglycans. Consequently they generate neocartilage with inferior mechanical 
properties as compared to articular cartilage or other chondrocyte cell sources (52). Like 
ACI, the use of meniscal chondrocytes is based on cells isolated from a biopsy and may 
predispose to secondary OA, as it can induce joint instability (53). Additionally, the 
meniscus is partially exposed to the same catabolic environment as the articular cartilage, 
which deteriorates the chondrogenic behavior of the meniscal chondrocyte (54). As 
meniscal chondrocytes have similar disadvantage compared to articular chondrocytes and 
produce inferior neocartilage compared to these cells, they are an unlikely cell source for 
articular cartilage repair strategies. 
 Taking all available alternative chondrocyte populations into consideration, it is 
obvious that none of the alternative chondrocyte sources are exposed to a mechanical 
challenge, which is comparable to the stimuli present in the articular joint. Nevertheless, 
chondrocytes from alternative sources surpass articular chondrocytes in availability, cell 
yield and proliferation capacity and might be suitable for patient groups where the access 
to articular chondrocytes is limited. 
 
Non-chondrocyte cell sources: morbidity versus control of differentiation 
 Recently much research has been dedicated to cell sources other than articular 
chondrocytes. This is mainly due to articular chondrocyte’s low availability and its 
limited expansion capability without loss of function. These alternative cell sources 
include amongst others synovial fibroblasts, periosteocytes and multipotent progenitor 
cells.  
 Page 11 of 32 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
Ce
ll 
so
ur
ce
s f
or
 a
rti
cu
la
r c
ar
til
ag
e 
re
pa
ir 
str
at
eg
ie
s: 
sh
ift
in
g 
fro
m
 m
on
o-
cu
ltu
re
s t
o 
co
-c
ul
tu
re
s (
do
i: 1
0.1
08
9/t
en
.T
EB
.20
12
.02
73
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
12 
 
Synovial fibroblasts are a part of the natural repair response to articular defects, as 
these cells tend to fill up non-treated defects with a fibrous matrix (55). Unfortunately, 
this matrix is, like the matrix produced by meniscal chondrocytes, mechanically weak 
and predominantly consists of collagen type 1 (56). Periosteocytes, depending on their 
site of isolation, possess chondrogenic potential that allows the formation of neocartilage 
(57). However, it has been suggested that this potential is inversely correlated with age. 
(58). In general, synovial fibroblast and meniscal chondrocytes have shown less promise 
compared to pluripotent/multipotent progenitor cells as an non-chondrocyte cell source. 
Pluripotent cells such as embryonic stem cells and induced-pluripotent stem cells 
are able to form de novo articular-like cartilage and can in theory be considered for 
cartilage repair strategies (59, 60). However, gaining absolute control on the prevention 
of teratoma formation is paramount when using these cells (61, 62). Until such control is 
acquired, it is unlikely that these cell sources will be clinically approved for treatment of 
non-lethal diseases such as articular cartilage repair.  
The best characterized progenitor cell sources for articular cartilage repair include 
mesenchymal stromal cells (MSCs) derived amongst others from bone marrow, 
periosteum, synovium, synovial fluid, adipose tissue, bucal fat pad, infrapatellar fat pad 
and osteoarthritic cartilage (63-67). Many other MSCs sources have remained largely 
uninvestigated for cartilage repair strategies and include amongst others umbilical cord 
blood, menstrual blood, muscles, ligaments, wartons jelly, amnion, chorion, breast milk 
and tonsil (68-75). Important factors deciding on which MSC source to use should not 
only be based on chondrogenic potential and phenotype, but also on cell yield, 
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accessibility, availability, age-related function decline, donor-site morbidity and 
acquisition costs. 
 Large inter-donor variation is a general complication encountered in all 
multipotent cell sources (76, 77). This is exacerbated by the influence of temporal culture 
conditions, methods of harvest and disputably donor age (57, 78-81). It has been 
suggested that distinct gene expression profiles might reflect their (chondrogenic) 
differentiation potential (82). However, the highly desired markers for chondrogenic 
differentiation potential of undifferentiated MSCs have so far remained undiscovered. 
Additionally, expansion of multipotent cells negatively affects chondrogenesis and might 
thereby possibly further confound therapeutic outcome (83, 84). 
MSCs are a heterogeneous population of cells. In consequence, both the 
maintenance of multipotency and chondrogenic potential of MSCs are greatly influenced 
by selection criteria, culture conditions in the expansion phase and optionally the 
differentiation phase. Criteria for the selection of MSCs were defined by the Society for 
Cellular Therapy in 2006. These criteria require adherence to tissue culture plastic, the 
expression of a panel of cell   surface markers (CD90
+
, CD105
+
, CD73
+
, HLA-DR
-
, 
CD45
-
, CD34
-
,CD11b
-
, CD19
-
) and the ability to differentiate into the adipogenic, 
osteogenic and chondrogenic lineage (85). Since then several further potential selection 
possibilities were published, including additional surface markers and distinct 
populations of MSCs that are found within the isolate (86-88). The classical view on 
optimizing the culture of mammalian cells is based on medium composition where much 
research has been focused on medium type and medium supplements (89-94). Non-
autologous medium supplements might hamper the clinical applicability of tissue 
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engineering strategies. Presently much attention is paid towards optimizing physiological 
factors, which influence cell behavior and thus therapy outcome, such as mechanical 
stress, substrate stiffness, substrate coating or chemistry and incubator gas composition in 
particular oxygen levels (95-103). Other physiological variables such as tonicity have 
remained largely uninvestigated. 
 Rather than using MSCs for chondrogenic differentiation and direct production of 
neocartilage, one can also take advantage of the immunomodulatory or trophic properties 
of MSCs (104). It is suggested that after reimplantation differentiated MSCs continue to 
modulate the immune response (105). This might be of high importance in allogeneic 
treatments (106). However, whether this modulation proves to be sufficient in tissues that 
are scarce in cells and rich in matrix, such as articular cartilage, remains to be further 
studied. Nonetheless, using allogeneic strategies allow for a decrease in the therapeutic 
inter-donor variation via the use of pools of multiple donors or selection of well 
performing donors.  
 Intra-articular injection of MSCs in a degenerating joint improves joint function 
and retards the development of osteoarthritis compared to untreated controls (107). 
However, tracking experiments have shown that only a fraction of the injected MSCs are 
integrated in or located near the affected cartilage (108). In fact, most MSCs are located 
in the joint capsule or migrated from the joint to seemingly unrelated tissues such as 
thymus, tongue, stomach, duodenum, jejunum and colon (109). Together this suggests 
that the MSCs at least partially act via an indirect mechanism, most likely via the 
secretion of trophic factors. Indeed, in vitro co-culture experiments demonstrated the 
anabolic effects of MSCs-derived trophic factors on chondrocytes (24). However, 
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whether the same trophic factors are responsible for the anabolic effects observed in vivo 
remains to be proven. 
 Although MSCs can be differentiated in many different cell types and might 
contribute to tissue repair via released factors, it remains to be noted that their 
differentiation process cannot be fully controlled in vivo. Spontaneous sarcoma formation 
has been observed in long term expanded murine MSCs and after injection in mice (110, 
111). Although this has not yet been reported in humans, the lack of full control over the 
behavioral phenotype of the MSCs remains a potential concern. For example, injections 
of MSCs in cancer therapy has both been described to restrict tumor growth by 
decreasing the division rate of benign cells as well as augment tumor growth by 
stimulating angiogenesis (112). These types of contradictions are not uncommon and 
underline the lack of deep understanding of the in-vivo behavior of MSCs. Absolute 
control of the selection and differentiation process of MSCs is essential if MSCs are to be 
used routinely for cell therapy such as articular cartilage repair. It can be conceived that 
more stringent selection criteria for the isolation of MSCs will result in a more 
homogenous and controllable cell source. However, this would also result a more 
prolonged expansion phase as many cells will be discarded, which might lead to (partial) 
loss of multipotency.  
 In vitro MSCs are differentiated into chondrocytes in serum free media 
supplemented with transferrin, insulin sodium selenite, Transforming Growth Factor beta 
1 or 3 (TGF-β 1 or 3), dexamethasone (113) and in some studies with BMP6. Since the 
optimal combination and concentration of growth factors remains unclear, chondrogenic 
differentiation of multipotent cells such as MSCs typically results in the formation of 
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neocartilage that is dissimilar to mature articular cartilage. However, it bears a striking 
phenotypical resemblance to fetal cartilage (114, 115). Moreover, chondrogenic 
differentiation of MSCs results in a gene expression profile that better resembles growth 
plate chondrocytes, which can differentiate into hypertrophic cartilage, than articular 
chondrocytes (116). Indeed, cartilage formed by differentiated MSCs displays typical 
signs of hypertrophic differentiation (117-119). In line with this, standard differentiation 
protocols currently used for chondrogenic differentiation of MSCs in vitro, are able to 
induce the expression of chondrogenic genes, like aggrecan and collagen 2, but do not 
express the recently identified articular cartilage enriched genes, like DKK1, GREM1 
and FRZB. These  secreted antagonists were proven to function as inhibitors of 
hypertrophic differentiation (116). Consequently, chondrogenically differentiated 
multipotent and pluripotent cells undergo endochondral ossification upon subcutaneous 
implantation (60, 120). Although this phenomenon is of notable interest for bone repair 
strategies, it is highly undesirable for cartilage repair strategies. Moreover, it 
demonstrates that current differentiation protocols, at least in vitro, are insufficient to 
yield articular-like cartilage and require improvement for reproducible cartilage repair 
strategies. Finally, it is of importance to note that the formation of functional neocartilage 
has been witnessed in orthotopic repair in animal models. This suggests that the joint 
microenvironment contains instructive stimuli for the formation of permanent articular 
cartilage (121). 
 
Co-cultures: combinatorial advantages versus current knowledge 
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 Performance of cell sources in cartilage formation can be augmented by making 
use of co-culture strategies. Co-cultures of different cell sources are based on the idea 
that the multi-signal events in vivo cannot be perfectly mimicked by adding a limited 
variety of growth factors to a mono-culture of which the optimal cocktail remains largely 
elusive. This problem can be circumvented by the introduction of another cell source in 
the culture. In this way, cells are exposed to a wider variety of stimuli. Moreover, the 
stimuli are based on autologous non-recombinant (secreted soluble) factors. In 
consequence, they could be considered as a preferred way of stimulation, as it omitting 
the remaining issues regarding the use of non-autologous recombinant factors in clinical 
settings. 
Three decades ago, the first co-culture experiments for cartilage tissue 
engineering were performed. First co-culture experiments mainly focused on revealing 
the pathological mechanisms of cartilage destruction by mixing chondrocytes with cell 
types that are potentially involved in cartilage catabolism (122, 123). More recently, co-
cultures that include chondrocytes have been investigated for their capacity to enhance 
neocartilage formation. In general three (partially overlapping) categories can be 
identified: i) co-cultures with unilateral beneficial effect of one cell type on neocartilage 
formation; ii) co-cultures with mutually beneficial effects on neocartilage formation; iii) 
co-cultures based on cell types with unique features that do not (directly) affect the 
behavior of the other cell type (Figure 1).  
Expansion of isolated autologous chondrocytes is commonly required to obtain 
sufficient amount of cells for reimplantation. This expansion induces dedifferentiation of 
the chondrocytes. Interestingly, co-culturing expanded dedifferentiated chondrocytes 
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with (previously frozen) primary chondrocytes can (partially) reverse their loss of 
phenotype (24, 124, 125) (Figure 1A). This redifferentiation appears to induce a stable 
phenotype; withdrawal of the exposure to primary chondrocytes does not lead to reversal 
of the effect (126). Alternatively, articular chondrocytes have been co-cultured with non-
articular chondrocytes (127). However, so far little attention has been focused on these 
types of chondrocyte-chondrocyte co-cultures. In consequence, many questions still 
linger before an in-depth understanding of their actual therapeutic value can be obtained. 
Presently, the most common co-cultures experiments investigate the effect of co-
culture on the differentiation of the used cell types, as well as on improving the tissue 
formation in engineered constructs. In 1999 Jikko et al. showed that co-culturing growth 
plate chondrocytes with articular chondrocytes inhibited the terminal differentiation of 
growth plate chondrocytes (128). In line with this, it has been demonstrated that addition 
of articular chondrocytes to MSCs inhibits hypertrophic differentiation of the latter. 
Although the mechanism behind this phenomenon remains largely unknown, some 
evidence suggests that this effect is mediated via parathyroid hormone-related protein 
(129). However, alternative explanations such as articular cartilage derived factors 
inhibiting hypertrophic chondrocyte differentiation have remained uninvestigated (116).  
The first studies in which MSCs were combined with other cell sources to provide 
a distinct effect included the vascularization of bone tissue engineered constructs (130, 
131) and improvement of matrix deposition in degenerative discs (132). In contrast, in 
cartilage repair strategies MSCs were initially used to reduce the amount of chondrocytes 
needed or to omit their use all together. Fascinatingly, chondro-induction was observed in 
these experiments; superior neocartilage was formed by the combination of two different 
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cell-types as compared to either cell type alone (Figure 1B) (24, 133). In this context, the 
co-culture of articular chondrocytes and MSCs is most commonly studied. It is claimed 
that this phenomenon can be explained by the induction of chondrogenic differentiation 
of MSCs by articular chondrocytes (65, 134-136). Indeed, the addition of articular 
chondrocyte-conditioned medium is able to instigate chondrogenic differentiation of 
MSCs (137). However, recent findings demonstrate that chondrocyte proliferation is 
enhanced by the presence of MSCs (24, 136). The MSCs accomplish this effect by acting 
as a trophic mediator. Moreover, while chondrogenic differentiation of MSCs can be 
triggered by chondrocytes, it also induces apoptosis in the MSCs (24). Although the 
majority of MSCs will undergo apoptosis, the remaining fraction displays a strong 
chondrogenic phenotype (24, 136). This effect of MSCs is mediated by an as yet 
unidentified soluble secreted mediator. This results in a progressive disappearance of the 
MCSs from the original co-culture. Further investigation has to demonstrate if MSCs 
eventually completely vanish from the co-culture. If indeed this holds true, it can be 
considered as a beneficial factor for the use of (pools of) allogeneic MSCs. Moreover, if 
MSCs indeed predominantly stimulate neocartilage formation indirectly by acting as a 
source of trophic factors, one might consider MSC implantation sites within the joint 
other than the cartilage defect as the secreted factors diffuse to the cartilage via the 
synovial fluid. Regardless, in light of these novel findings the direct contribution of the 
MSCs to cartilage matrix deposition is still unclear. In addition, the question whether 
chondro-induction is induced due to exposure of factors normally produced by the 
opposite cell type or whether the co-culturing induces the expression of factors otherwise 
not expressed in either cell type remains to be answered.  
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Alternative strategies to improve neocartilage formation using co-cultures include 
the generation of articular cartilage’s zonal architecture (Figure 1C). In recent years novel 
cartilage repair strategies have been designed that aim at mimicking this anisotropic 
organization (138, 139). Co-cultures in combination with multilayer three-dimensional 
printing or layer-by-layer methodology using hydrogels that are able to covalently link by 
residual reactive residues e.g. dextran-tyramine gels (140-143) can further enhance these 
strategies. Calcifying cells, or their precursors, can be used for the deep zone, intensive 
extracellular matrix producing calcification resistant cells for the middle zone, and less 
intensive extracellular matrix producing and lubricin secreting cells for the superficial 
zone. Furthermore, for example, osteoblasts and chondrocytes can be co-cultured in 
different regions of a construct to allow the formation of an osteochondral interface (144, 
145). However, as only a scarce number of studies have been reported on such an 
approach, the feasibility remains to be determined. 
 
Conclusion 
The therapeutic outcome of cell-based therapies does not solely rely on the 
performance of the implanted cells. It also heavily relies on the expansion conditions and 
exogenous stimuli. In addition, functionalized biomaterials currently under development 
and which can  be used as carriers for cell implantation, are expected to provide a 
platform for controlling cellular phenotype in the near future. Subsequently, these factors 
can result in dissimilar responses in different cell sources. In short, much research 
remains to be performed in order to identify the combinations leading to optimal clinical 
results. The wide range of cell sources available to cartilage tissue engineers grants an 
optimal starting point for future improvement of cartilage repair strategies. Specifically, 
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the combination of different cell sources currently holds great promise as it is able to 
grant combinatorial advantages by combining the benefits while mitigating the 
disadvantages of unique cell types. 
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Figure 1: Different types of chondrocyte based co-cultures. (A) The addition of freshly 
isolated chondrocytes promotes the redifferentiation of expanded dedifferentiated 
chondrocytes. (B) Co-culturing MSCs with chondrocytes results in the enhanced 
proliferation and matrix deposition of the chondrocytes via MSC-derived soluble factors. 
Additionally, chondrocytes induce controlled cell death of MSC, which results in a strong 
decline of MSCs in the co-culture. The remaining MSCs undergo chondrogenic 
differentiation, which is driven by chondrocyte-derived soluble factors. (C) Layered 
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deposition of different cell types can be utilized to obtain a zonally structured construct, 
which display unique features in the distinct zones. For example, layering lubricin 
producing cells, chondrocytes and bone forming cells can be explored to form an 
osteochondral construct that mimics the native tissue. 
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